IL157254A0 - N-substituted nonaryl-heterocyclic nmda/mr2b antagonists - Google Patents

N-substituted nonaryl-heterocyclic nmda/mr2b antagonists

Info

Publication number
IL157254A0
IL157254A0 IL15725402A IL15725402A IL157254A0 IL 157254 A0 IL157254 A0 IL 157254A0 IL 15725402 A IL15725402 A IL 15725402A IL 15725402 A IL15725402 A IL 15725402A IL 157254 A0 IL157254 A0 IL 157254A0
Authority
IL
Israel
Prior art keywords
mr2b
antagonists
nmda
heterocyclic
nonaryl
Prior art date
Application number
IL15725402A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23034191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL157254(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL157254A0 publication Critical patent/IL157254A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
IL15725402A 2001-02-23 2002-02-20 N-substituted nonaryl-heterocyclic nmda/mr2b antagonists IL157254A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27110001P 2001-02-23 2001-02-23
PCT/US2002/005226 WO2002068409A1 (en) 2001-02-23 2002-02-20 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists

Publications (1)

Publication Number Publication Date
IL157254A0 true IL157254A0 (en) 2004-02-19

Family

ID=23034191

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15725402A IL157254A0 (en) 2001-02-23 2002-02-20 N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
IL157254A IL157254A (en) 2001-02-23 2003-08-05 Heterocyclic aryl - N - are transformed into non-aryl and their use in the preparation of pain medications

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL157254A IL157254A (en) 2001-02-23 2003-08-05 Heterocyclic aryl - N - are transformed into non-aryl and their use in the preparation of pain medications

Country Status (33)

Country Link
US (2) US7217716B2 (xx)
EP (1) EP1379520B2 (xx)
JP (1) JP4179879B2 (xx)
KR (1) KR100849839B1 (xx)
CN (1) CN100567293C (xx)
AT (1) ATE324371T1 (xx)
AU (1) AU2002252053B2 (xx)
BG (1) BG108113A (xx)
BR (1) BR0207526A (xx)
CA (1) CA2438895A1 (xx)
CZ (1) CZ20032258A3 (xx)
DE (1) DE60210944T3 (xx)
DK (1) DK1379520T3 (xx)
EA (1) EA005974B1 (xx)
EC (1) ECSP034744A (xx)
EE (1) EE200300403A (xx)
ES (1) ES2261658T3 (xx)
GE (1) GEP20063741B (xx)
HR (1) HRP20030669A2 (xx)
HU (1) HUP0303258A3 (xx)
IL (2) IL157254A0 (xx)
IS (1) IS6902A (xx)
MX (1) MXPA03007621A (xx)
NO (1) NO20033732L (xx)
NZ (1) NZ527365A (xx)
PL (1) PL364625A1 (xx)
PT (1) PT1379520E (xx)
SI (1) SI1379520T1 (xx)
SK (1) SK10542003A3 (xx)
UA (1) UA75392C2 (xx)
WO (1) WO2002068409A1 (xx)
YU (1) YU64303A (xx)
ZA (1) ZA200306159B (xx)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2449249A1 (en) * 2001-06-12 2002-12-19 Merck & Co., Inc. Nr2b receptor antagonists for the treatment or prevention of migraines
US7163952B2 (en) * 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE366045T1 (de) * 2002-03-15 2007-07-15 Ciba Sc Holding Ag Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1502916A4 (en) 2002-04-16 2006-05-31 Teijin Ltd Piperidin derivatives with CCR3-antagonism
JP4429738B2 (ja) 2002-04-25 2010-03-10 帝人株式会社 Ｃｃｒ３拮抗作用を有する４，４−二置換ピペリジン誘導体
JP2004315511A (ja) * 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Ｍｃｈ受容体アンタゴニスト
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
WO2004108705A1 (en) * 2003-06-04 2004-12-16 Merck & Co., Inc. 3-fluoro-piperidines as nmda/nr2b antagonists
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
EP1713781B1 (en) 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
AU2005271669A1 (en) * 2004-08-03 2006-02-16 Merck & Co., Inc. 1,3-disubstituted heteroaryl NMDA/NR2B antagonists
AU2005281783A1 (en) * 2004-09-10 2006-03-16 Ucb Pharma, S.A. Sigma receptor ligands
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP2308840A1 (en) 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
US20080269251A1 (en) * 2005-12-21 2008-10-30 Jose Ignacio Andre-Gil Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists
WO2007099828A1 (ja) * 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
US20100273776A1 (en) * 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2007328981B2 (en) * 2006-12-08 2013-07-11 F. Hoffmann-La Roche Ag Substituted pyrimidines and their use as JNK modulators
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
MX2009007610A (es) 2007-02-06 2009-07-24 Boehringer Ingelheim Int Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
RS52518B (en) * 2007-04-23 2013-04-30 Janssen Pharmaceutica N.V. 4-ALCOXYPYRIDASINE DERIVATIVES AS A FAST DISSOCATING DOPAMINE 2 RECEPTOR ANTAGONISTS
EP2148879B1 (en) 2007-04-23 2012-11-28 Janssen Pharmaceutica, N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
PT2195293E (pt) 2007-08-22 2014-01-21 Astrazeneca Ab Derivados da ciclopropilamida
WO2009058261A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
NZ589883A (en) 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
CN102159554B (zh) 2008-07-03 2014-09-24 詹森药业有限公司 作为5-ht6受体拮抗剂的取代的6-(1-哌嗪基)-哒嗪
HUE033768T2 (en) 2008-07-31 2017-12-28 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted pyridines as rapidly dissociating dopamine-2 receptor antagonists
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
RU2012136148A (ru) 2010-02-18 2014-03-27 Астразенека Аб Новая кристаллическая форма производного циклопропилбензамида
AU2011218490B9 (en) * 2010-02-18 2014-12-18 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9388140B2 (en) * 2011-03-31 2016-07-12 Bayer Intellectual Property Gmbh Substituted benzimidazoles
EP2760856B1 (en) * 2011-09-30 2016-09-14 Bristol-Myers Squibb Company Selective nr2b antagonists
JP6042968B2 (ja) 2012-04-20 2016-12-14 ユセベ ファルマ ソシエテ アノニム パーキンソン病の処置方法
JP2016028017A (ja) * 2012-12-13 2016-02-25 大正製薬株式会社 フッ素置換ピペリジン化合物
JP2017001954A (ja) * 2013-11-08 2017-01-05 石原産業株式会社 含窒素飽和複素環化合物
EP3150598B1 (en) * 2014-05-28 2019-02-13 TOA Eiyo Ltd. Substituted tropane derivatives
EP3152213B1 (en) * 2014-06-04 2018-10-31 Rugen Holdings (Cayman) Limited Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists
RU2017107558A (ru) * 2014-09-15 2018-10-18 Руджен Холдингс (Кайман) Лимитед Производные пирролопиримидина в качестве антагонистов nmda-рецептора nr2b
WO2016100349A2 (en) * 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
WO2016126869A1 (en) 2015-02-04 2016-08-11 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
PE20180327A1 (es) * 2015-05-11 2018-02-13 Basf Se Proceso para preparar 4-amino-piridazinas
KR102613179B1 (ko) 2015-06-01 2023-12-14 뤼겐 홀딩스 (케이맨) 리미티드 Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
EP3589632B1 (en) * 2018-02-23 2020-09-23 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Novel inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL265777A (xx) 1960-06-09
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
EP0126087A1 (en) * 1982-09-24 1984-11-28 Beecham Group Plc Amino-azabicycloalkyl derivatives as dopamine antagonists
HU222726B1 (hu) 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
DK0554247T3 (da) 1990-05-10 2000-08-07 Pfizer Neurobeskyttende indolon og beslægtede derivater
US5189036A (en) 1990-06-20 1993-02-23 Schering Ag Imidazolylbenzoyl substituted heterocycles
JPH0788355B2 (ja) 1991-04-18 1995-09-27 フアイザー・インコーポレイテツド フェノール性２―ピペリジノ―１―アルカノールのプロドラグエステル
HUT70528A (en) 1991-07-17 1995-10-30 Pfizer 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents and process for production thereof
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
SI9300097B (en) * 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
SG63579A1 (en) 1992-12-21 1999-03-30 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CA2157412A1 (en) 1993-03-03 1994-09-15 Julia Marie Heerding Balanoids
US5714498A (en) 1993-03-18 1998-02-03 Merck, Sharp, & Dohme, Ltd. Benzimidazole derivatives
AU3138595A (en) 1994-07-20 1996-02-16 Acea Pharmaceuticals, Inc. Haloperidol analogs and the use thereof
US5661161A (en) 1994-09-29 1997-08-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0742208A1 (en) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamide derivatives
DK0828513T3 (da) 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
DE19541264A1 (de) 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
DE69620974T2 (de) 1995-11-06 2003-01-16 Kuraray Co., Ltd Verfahren zur Herstellung von Acetalen
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
EP0787493A1 (en) 1996-02-03 1997-08-06 F. Hoffmann-La Roche Ag Tetrahydroisoquinoline derivatives
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
WO1997045119A1 (en) 1996-05-24 1997-12-04 Novartis Ag Use of substance p antagonists for treating social phobia
EP0917462B1 (en) 1996-07-25 2006-09-13 Biogen Idec MA Inc. Cell adhesion inhibitors
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0846683B1 (en) 1996-12-03 2001-09-19 F. Hoffmann-La Roche Ag 4-Hydroxy-piperidine derivatives
FR2758327B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles arylpiperazines derivees de piperidine
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
IT1291569B1 (it) 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
US6020347A (en) 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
WO1999025685A1 (en) 1997-11-18 1999-05-27 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
DE19815026A1 (de) * 1998-04-03 1999-10-07 Hoechst Schering Agrevo Gmbh Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
US6235755B1 (en) 1998-08-07 2001-05-22 Applied Research Systems Ars Holding N.A. FSH mimetics for the treatment of infertility
DE19838300A1 (de) 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
CA2368049A1 (en) 1999-04-13 2000-10-19 Basf Aktiengesellschaft Integrin receptor ligands
JP2003503351A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害化合物

Also Published As

Publication number Publication date
KR20030076703A (ko) 2003-09-26
ZA200306159B (en) 2004-07-05
AU2002252053C1 (en) 2002-09-12
WO2002068409A1 (en) 2002-09-06
KR100849839B1 (ko) 2008-08-01
AU2002252053B2 (en) 2006-09-14
DE60210944D1 (de) 2006-06-01
EP1379520A1 (en) 2004-01-14
ATE324371T1 (de) 2006-05-15
HUP0303258A2 (hu) 2004-01-28
PT1379520E (pt) 2006-08-31
GEP20063741B (en) 2006-02-10
DK1379520T3 (da) 2006-08-21
DE60210944T3 (de) 2015-07-23
IL157254A (en) 2008-11-26
YU64303A (sh) 2006-05-25
SK10542003A3 (sk) 2004-03-02
CN1503793A (zh) 2004-06-09
US7217716B2 (en) 2007-05-15
NO20033732L (no) 2003-10-22
US7053089B2 (en) 2006-05-30
UA75392C2 (en) 2006-04-17
BR0207526A (pt) 2004-03-09
CA2438895A1 (en) 2002-09-06
ECSP034744A (es) 2003-10-28
PL364625A1 (en) 2004-12-13
EA200300919A1 (ru) 2004-02-26
DE60210944T2 (de) 2007-04-19
US20020165241A1 (en) 2002-11-07
SI1379520T1 (sl) 2006-08-31
NO20033732D0 (no) 2003-08-22
EP1379520B1 (en) 2006-04-26
MXPA03007621A (es) 2003-12-04
CN100567293C (zh) 2009-12-09
BG108113A (bg) 2005-04-30
JP2004524314A (ja) 2004-08-12
NZ527365A (en) 2005-08-26
CZ20032258A3 (cs) 2004-01-14
IS6902A (is) 2003-07-31
US20040209889A1 (en) 2004-10-21
ES2261658T3 (es) 2006-11-16
EA005974B1 (ru) 2005-08-25
JP4179879B2 (ja) 2008-11-12
EE200300403A (et) 2003-12-15
EP1379520B2 (en) 2014-04-09
HRP20030669A2 (en) 2005-06-30
HUP0303258A3 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
IL157254A0 (en) N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
IL161074A0 (en) Lactam derivatives as antagonists for human 11cby receptors
DE60329001D1 (en) 8-hydroxychinolinderivate
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
WO2002074758A3 (en) Novel amines as histamine-3 receptor ligands and their therapeutic applications
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
NO20052182L (no) Nye forbindelser
UA84712C2 (xx) N-заміщені піразоліламідилбензімідазоліли як c-kit інгібітори$n-замещенные пиразолиламидилбензимидазолилы как c-kit ингибиторы
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
MXPA04010625A (es) Antagonista de receptor de taquicinina.
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
AU2003239389A1 (en) Opioid receptor antagonists
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
IL157540A0 (en) N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
MXPA03009723A (es) Procedimientos e intermediarios para preparar epoxidos substituidos de bencilo.
ATE491709T1 (de) Pyrrolidinohydrochinazoline
DE60214397D1 (en) 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität
AU2002359762A1 (en) Luminacin analogs and uses thereof
TW200740442A (en) Therapeutic agent for hypertension

Legal Events

Date Code Title Description
FF Patent granted